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Abstract
Background: Activation of p53-mediated gene transcription is a critical cellular response to DNA
damage and involves a phosphorylation-acetylation cascade of p53. The discovery of differences in the
response to different agents raises the question whether some of the p53 oncosuppressor functions might
be exerted by different posttranslational modifications. Stress-induced homeodomain-interacting protein
kinase-2 (HIPK2) phosphorylates p53 at serine-46 (Ser46) for p53 apoptotic activity; p53 acetylation at
different C-terminus lysines including p300-mediated lysine-382 (Lys382) is also required for full activation
of p53 transcriptional activity. The purpose of the current study was to evaluate the interplay among
HIPK2, p300, and p53 in p53 acetylation and apoptotic transcriptional activity in response to drug by using
siRNA interference, p300 overexpression or deacetylase inhibitors, in cancer cells.
Results: Knockdown of HIPK2 inhibited both adriamycin-induced Ser46 phosphorylation and Lys382
acetylation in p53 protein; however, while combination of ADR and zinc restored Ser46 phosphorylation
it did not recover Lys382 acetylation. Chromatin immunoprecipitation studies showed that HIPK2 was
required in vivo for efficient p300/p53 co-recruitment onto apoptotic promoters and that both p53
modifications at Ser46 and Lys382 were necessary for p53 apoptotic transcription. Thus, p53Lys382
acetylation in HIPK2 knockdown as well as p53 apoptotic activity in response to drug could be rescued by
p300 overexpression. Similar effect was obtained with the Sirt1-inhibitor nicotinamide. Interestingly
trichostatin A (TSA), the inhibitor of histone deacetylase complexes (HDAC) did not have effect,
suggesting that Sirt1 was the deacetylase involved in p53 deacetylation in HIPK2 knockdown.
Conclusion: These results reveal a novel role for HIPK2 in activating p53 apoptotic transcription. Our
results indicate that HIPK2 may regulate the balance between p53 acetylation and deacetylation, by
stimulating on one hand co-recruitment of p300 and p53Lys382 on apoptotic promoters and on the other
hand by inhibiting Sirt1 deacetylase activity. We attempted to reactivate p53 apoptotic transcriptional
activity by rescuing both Ser46 and Lys382 modification in response to drug. Our data propose
combination strategies for the treatment of tumors with dysfunctional p53 and/or HIPK2 that include
classical chemotherapy with pharmacological or natural agents such as Sirt1-deacetylase inhibitors or zinc,
respectively.
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Background
The tumor suppressor p53 plays a critical role in the pre-
vention of human cancer and in tumor response to chem-
otherapy. As a transcription factor that both activates and
represses target genes p53 demands a highly complicated
network to control and fine-tune responses to the differ-
ent stress-signals encountered [1]. Stress-induced modifi-
cations of p53 variously implicated in protein stability
and/or transcriptional activity include phosphorylation,
acetylation, and ubiquitylation, as well as conformational
changes and interactions with other proteins [2]. Much
interest was lately given on what specific p53 posttransla-
tional modification can affect specific p53 oncosuppres-
sor outcome. It has been proposed that Ser46
phosphorylation is a late event after DNA damage that
triggers irreversible apoptosis by shifting p53 from cell-
cycle-related to apoptosis-related gene transcription (e.g.,
p53AIP1 gene) [3,4]. We have previously shown that
homeodomain-interacting protein kinase-2 (HIPK2)
phosphorylates p53 at N-terminal Ser46 enhancing p53
apoptotic [5]. Thus, HIPK2-induced Ser46 phosphoryla-
tion activates several p53 targets involved in both intrinsic
and extrinsic apoptotic pathway [5-7]. However, Ser46
phosphorylation is not always sufficient to induce apop-
tosis in all cell types suggesting that multiple mechanisms
of regulation of p53 might exist [8].
Full activation of p53 transcriptional function involves
also p53 acetylation by coactivators/histones acetyl-trans-
ferases (HATs) that occurs specifically in the C-terminal
regulatory regions surrounding the tetramerization
domain [9-11] and facilitates the recruitment of HATs to
p53 target promoters [12]. Phosphorylation of p53 N-ter-
minal residues permits the interaction of p53 with CBP/
p300, which acetylates p53 lysine-382 (Lys382) and with
PCAF, which acetylates p53 lysine-320 [13]. This is fol-
lowed by an increase in p53 stability and sequence-spe-
cific DNA-binding activity, both in vitro and  in vivo,
possibly due to conformational changes [9,11,13,14]. It
has been shown that HIPK2 and CBP/p300 show a
mutual interaction and that HIPK2-mediated phosphor-
ylation of p53Ser46 is required for the CBP-mediated p53
acetylation [15]. Moreover, HIPK2 interacts with p300
and HIPK2-mediated phosphorylation of p300 stimulates
its acetyl-transferase (HAT) activity [16]. These data sug-
gest a complex interplay among HIPK2, p300, and p53
and indicate that HIPK2 may act at multiple levels to fine-
tune transcriptional activity of p53 in tumor cells sub-
jected to genotix stress.
A tight regulation of p53 acetylation in vivo implies also
the involvement of deacetylases [13]. In this regard, it has
been shown that Lys382 of p53 is a substrate for the Sirt1
(NAD-dependent histone deacetylase)-mediated
deacetylation which antagonizes p53-dependent tran-
scriptional activation and apoptosis in response to DNA
damage and oxidative stress [17,18]. Sirt1-deficient mice
display increased levels of radiation-induced apoptosis
and p53 hyperacetylation [19]. On the other hand, p53
can repress Sirt1 transcription as shown by Tp53-null mice
with increased levels of Sirt1 in various tissue types as well
as by several p53-null tumor cells lines with Sirt1 overex-
pression [20,21]. These findings underline the role of p53
transcription activity for a proper Sirt1/p53 regulatory
feedback loop to induce p53 oncosuppressor function.
We reported previously that HIPK2 knockdown by RNA
interference results in p53 protein misfolding with abla-
tion of p53 transcriptional activity and that zinc restores
wtp53 native conformation, DNA binding, and transcrip-
tional activity [22]. Unravelling the modes of p53 tran-
scriptional selection is a key factor in the understanding of
how p53 is able to choose life or death for the cell. In this
report, in order to understand how different p53 post-
translational modifications and proteins interactions are
involved in influencing p53 promoter selection we evalu-
ated the role of HIPK2 in Ser46 and Lys382 modifications
for p53 apoptotic transcription. We found that combina-
tion of ADR and zinc in HIPK2 knockdown cells restored
Ser46 phosphorylation but it did not recover Lys382
acetylation. We found that p300 and p53Lys382 were co-
recruited onto apoptotic promoters and that both Ser46
phosphorylation and Lys382 acetylation were necessary
for efficient p53 apoptotic transcriptional activity in
response to drug. Lack of Lys382 acetylation in HIPK2
knockdown did not depend on p300 downmodulation
but could rather depend on impaired p53/p300 interac-
tion, as suggested by the ChIP analysis and/or on
increased deacetylase activity, as suggested by increased
Sirt1 levels. Lys382 acetylation in HIPK2 knockdown and
p53 apoptotic transcriptional activity could be restored in
response to drug by p300 overexpression or by the use of
the Sirt1 physiological inhibitor nicotinamide in combi-
nation with drug and zinc.
Our results show that p53Ser46 phosphorylation could be
obtained in response to drug even in the absence of
HIPK2, while HIPK2 knockdown strongly impaired
Lys382 acetylation and consequently p53 apoptotic tran-
scriptional activity. As p53 apoptotic function is often
deregulated in tumors by different mechanisms, our
results indicate that low HIPK2 expression is a potential
marker for p53 dysfunction, tumor progressions, and
chemoresistance; they also suggest some strategies, com-
bining chemotherapy with pharmacological or natural
agents, aimed at restoring p53 apoptotic transcriptional
function in tumors with non-functional wtp53 and/or
HIPK2.Molecular Cancer 2009, 8:85 http://www.molecular-cancer.com/content/8/1/85
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Results
Lack of p53Lys382 acetylation impairs in vivo p53 binding 
to apoptotic gene promoters when HIPK2 is 
underexpressed
We recently reported that zinc supplementation to ADR-
treated HIPK2 depleted cells (siHIPK2) shifts the mis-
folded p53 protein into wild-type conformation, restoring
p53 DNA binding and transactivation function as well as
Ser46 phosphorylation [22,23]. To gain insight into the
re-establishment of the p53 pathways when HIPK2 is
underexpressed Ser46 phosphorylation and Lys382
acetylation were first analysed by Western immunoblot-
ting. As shown in Figure 1a, knockdown of HIPK2
(siHIPK2), obtained with pSuper-HIPK2 transfection (not
shown), inhibited both ADR-induced Ser46 phosphoryla-
tion, and Lys382 acetylation; however, while combina-
tion of ADR and zinc restored Ser46 phosphorylation it
did not recover Lys382 acetylation (ac-p53Lys382). Inter-
estingly, ADR and zinc combination did not induce Bax
expression in HIPK2 depleted cells (Figure 1a), compared
to control cells, although it induced a good level of apop-
tosis, as assessed by TUNEL assay (Figure 1b), raising the
question whether lack of Lys382 acetylation by HIPK2
depletion could compromise p53 apoptotic response.
Lack of ac-p53Lys382 in response to combination of ADR
and zinc did not depend on p300 protein downmodula-
tion as p300 protein levels were similarly expressed in
siRNA control and siHIPK2 cells (Figure 1b). In addition,
Western immunoblotting showed that Sirt1 levels were
downmodulated by ADR in control cells while they were
not affected by ADR alone or in combination with zinc in
HIPK2-depleted cells (Figure 1c). These findings suggest
that zinc, likely by reconstitution of wtp53 conformation
as previously reported by us [22], allowed ADR-induced
Ser46 phosphorylation in siHIPK2 cells possibly by other
kinases known to phosphorylate Ser46 after ADR treat-
ment [24]. They also suggest that HIPK2 was required to
mediate p53Lys382 acetylation by p300 or by suppressing
Sirt1 deacetylase activity.
To test these hypotheses we determined the requirement
of HIPK2 in p53/p300 co-recruitment and Lys382 acetyla-
tion for p53 binding to apoptotic promoters and the phys-
iological relevance for apoptotic transcriptional activity
by ChIP, luciferase assays, and RT-PCR analysis. We took
advantage of the inducible HIPK2 knockdown in the
MCF7-indsi/HIPK2 cell line [23] that allows a reversible
HIPK2 depletion by doxycyclin (+Dox) treatment and
HIPK2 reconstitution after Dox removal (-Dox) from cell
culture medium. A representation of HIPK2 mRNA
expression after Dox treatment (+Dox) and after Dox
removal (-Dox) was shown by reverse-transcriptase (RT)-
PCR analysis (Figure 2a); those conditions of HIPK2
depletion and reconstitution were then used for the fol-
lowing experiments. Chromatin immunoprecipitation
with or without Dox (and therefore in the absence or pres-
ence of endogenous HIPK2, respectively), in the presence
or absence of ADR treatment, was carried out with anti-
p53 and anti-ac-p53Lys382 antibodies. PCR analysis
showed efficient p53 recruitment in response to ADR onto
(apoptotic) p53AIP1, Puma, and (growth-control) BTG2
gene promoters in HIPK2 wild-type cells. However the ac-
p53Lys382 was recruited only onto p53AIP1 and Puma
promoters (Figure 2b). Following HIPK2 depletion
(+Dox), p53 was no longer bound to the apoptotic pro-
moters while the binding was re-established after Dox
removal (-Dox) (Figure 2b); again, after HIPK2 reconstitu-
tion (-Dox) ac-p53Lys382 was recruited only onto apop-
totic promoters (Figure 2b), suggesting an involvement of
p300 in ac-p53Lys382 binding to the apoptotic promot-
ers. To verify this hypothesis, ChIP and Re-ChIP experi-
ment was performed. Chromatin complexes of RKO cells
transfected with siRNA control and treated with ADR were
immunoprecipitated with anti-p53, anti-ac-
p53Lys373&382, and anti-PAN-acetylated Histone H4
(ac-H4) antibodies and PCR analysis was performed using
specific primers flanking the p53 sequence-specific pro-
moter regions. We found that p53 was efficiently recruited
in vivo, in response to ADR, onto p53AIP1, Puma, and
BTG2 gene promoters, which also increased H4 histone
acetylation suggesting an open chromatin structure of the
tested promoters (Figure 2c, ChIP panel); notably, p53
immunoprecipitated with anti-ac-Lys373/382 antibody
was recruited only onto apoptotic gene promoters
p53AIP1 and Puma (Figure 2c, ChIP panel) suggesting an
involvement of p300 in p53 binding to apoptotic promot-
ers. Therefore, Re-ChIP analysis was performed by immu-
noprecipitating the p53-containing complexes with an
antibody against p300 such that only those DNA
sequences that are simultaneously bound by both pro-
teins would be amplified by the PCR. As shown in Figure
2c (Re-ChIP, panel), p53 and p300 were co-recruited only
onto the apoptotic gene promoters p53AIP1 and Puma
where the ac-Lys373/382 was recruited. Conversely, ChIP
analysis performed in siHIPK2 cells showed that p53 and
ac-H4 were readily recruited only onto BTG2 promoter
following zinc supplementation to ADR treatment while
they were not recruited onto apoptotic promoters
p53AIP1 and Puma (Figure 2d). In agreement, Re-ChIP
analysis performed in siHIPK2 cells failed to show p53
and p300 binding to promoters (data not shown).
Remarkably, apoptotic gene transcription in vivo of
p53AIP1 and Puma genes was obtained only in the pres-
ence of HIPK2, after ADR treatment (Figure 2e). These
results suggest that HIPK2 is involved in vivo in Lys382
acetylation and in p53/p300 co-recruitment onto apop-
totic gene promoters and that Ser46 phosphorylation, as
rescued by ADR and zinc combination (Figure 1a), wasMolecular Cancer 2009, 8:85 http://www.molecular-cancer.com/content/8/1/85
Page 4 of 14
(page number not for citation purposes)
Analysis of p53Lys382 acetylation, p53Ser46 phosphorylation, Bax, p300 and Sirt1 protein levels, in HIPK2 knockdown in  response to ADR and zinc treatment Figure 1
Analysis of p53Lys382 acetylation, p53Ser46 phosphorylation, Bax, p300 and Sirt1 protein levels, in HIPK2 
knockdown in response to ADR and zinc treatment. (a) RKO cells transfected with pSuper-HIPK2 (siHIPK2) or pSuper 
control (siRNA C) for 24 h were treated with ADR (2 μg/ml) and ZnCl2 (150 μM) for 16 h. After treatment, equal amounts of 
total cell extracts were subjected to Western immunoblotting using specific antibodies as indicated. Anti-Hsp70 was used as 
protein loading control. (b) RKO cell depleted of HIPK2 function by siRNA were treated with ADR and zinc and 24 h and 
apoptosis was measured by TUNEL assay and shown as percentage of TUNEL positive cells. The results shown are represent-
ative of two independent experiments performed in duplicate, ± S.D. (c) Equal amount of nuclear cell extracts of RKO cells 
depleted of HIPK2 function as in (a) and treated with ADR (2 μg/ml) for 16 h were analysed by Western immunoblotting with 
anti-p300 antibody. Anti-Hsp70 was used as protein loading control. (d) Equal amount of total cell extracts of RKO-HIPK2-
depleted cells as in (a) and treated with ADR (2 μg/ml) for 16 h were analysed by Western immunoblotting with anti-Sirt1 anti-
body. Anti-tubulin was used as protein loading control.Molecular Cancer 2009, 8:85 http://www.molecular-cancer.com/content/8/1/85
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HIPK2 stimulates co-recruitment of p53Lys382 and p300 on apoptotic promoters Figure 2
HIPK2 stimulates co-recruitment of p53Lys382 and p300 on apoptotic promoters. (a) MCF7/indsi/HIPK2 cells 
were treated with Dox (+Dox) for 5 days (for HIPK2 knockdown) and then cultured without Dox (-Dox) for additional 5 days 
(for HIPK2 recover) before analysing HIPK2 expression by RT-PCR. GAPDH was used as a control of efficiency for RNA 
extraction and transcription. (b) ChIP analysis with antibodies specific for p53 and p53 acetylated on Lys382 was performed 
with MCF7indsi/HIPK2 cells treated with Dox for 5 days and then cultured without Dox for additional 5 days, with or without 
ADR (2 μg/ml) treatment for 16 h. PCR analyses were performed on the immunoprecipitated DNA samples using specific 
primers for p53 target promoters, as indicated. (c) ChIP analysis with antibodies specific for p53, p53 acetylated on Lys373/382 
and PAN-acetylated Histone H4 (ac-H4) was performed with RKO cells, transfected with siRNA control, left untreated or 
treated with ADR (2 μg/ml) for 16 h. Re-ChIP analysis was performed by immunoprecipitating the p53-containing complexes 
with an antibody against p300. PCR analysis was performed on the immunoprecipitated DNA samples using specific primers for 
p53 target promoters. A sample representing linear amplification of the total input chromatin (Input) was included as control. 
Additional controls included immunoprecipitation performed with non-specific immunoglobulins (No Ab). (d) ChIP analysis 
with antibody specific for p53 and PAN-acetylated Histone H4 (ac-H4) was performed with RKO cells stable depleted of 
HIPK2 function by pSuper-HIPK2 transfection (siHIPK2) and treated with ADR (2 μg/ml) and zinc (150 μM) for 16 h. PCR anal-
ysis was performed on the immunoprecipitated DNA samples using specific primers for p53 target promoters. A sample rep-
resenting linear amplification of the total input chromatin (Input) was included as control. Additional controls included 
immunoprecipitation performed with non-specific immunoglobulins (No Ab). (e) MCF7indsi/HIPK2 cells were treated as in (b) 
and induction of p53 target genes p53AIP1 and Puma was evaluated by semiquantitative RT-PCR, with GAPDH serving as con-
trol.Molecular Cancer 2009, 8:85 http://www.molecular-cancer.com/content/8/1/85
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not sufficient to induce p53 binding to apoptotic promot-
ers when p300 co-recruitment and Lys382 acetylation of
p53 were impaired in HIPK2-depleted cells.
HIPK2 influences p53 apoptotic gene transcription 
depending on p53 site-specific acetylation
Here we found that HIPK2 is involved also in Lys382
acetylation that affected p53 binding to apoptotic pro-
moters. We then aimed to assess the functional relevance
of the above observations. We have previously demon-
strated that RKO undergoes apoptosis and that HIPK2
depletion inhibits p53-dependent apoptosis [6,22] (Addi-
tional file 1, Table S1). To gain further insight into the re-
establishment of the p53 pathways, we compared gene
expression pattern of RKO-siHIPK2 cells treated with ADR
and zinc, by cDNA micorarray analyses. We found that
treatment with ADR and zinc combination did not restore
the p53 apoptotic gene transcription (data not shown).
Then we tested the apoptotic transcriptional activity of
p53 on p53AIP1-luciferase reporter and found that p53 in
siHIPK2 cells was highly impaired in inducing p53AIP1-
luc activity in response to ADR, compared to siRNA con-
trol cells, even after zinc supplementation (Figure 3a),
confirming that Ser46 phosphorylation alone without
Lys382 acetylation was not sufficient to induce p53 apop-
totic transcriptional activity of the luciferase reporter ana-
lysed. To assess the impact of HIPK2-induced p53
posttranslational modifications on p53 specific activation
of proapoptotic gene promoters the transcriptional activ-
ity of wtp53 compared to that of p53 mutants following
HIPK2 overexpression was evaluated in a p53/null cell
line (H1299). Both wtp53 and Q373 mutant (mimicking
constitutive acetylation of residues 370, 372, 373)
induced Noxa-luc reporter activity that was further
increased by HIPK2 (Figure 3b), that likely favoured also
Lys382 acetylation other than inducing Ser46 phosphor-
ylation, while the nonacetylatable K382R mutant did not
induce Noxa-luc activity even after HIPK2 overexpression.
Remarkably, mutation of Ser46 to alanine strongly
reduced the Q373-mediated Noxa-luc activity that obvi-
ously could not be increased by HIPK2 (Figure 3b). Simi-
lar results were obtained with p53AIP1-luc reporter (data
not shown). These results indicate that HIPK2-dependent
p53 apoptotic transcriptional activity is fully functioning
only when p53 is posttranslational modified at both
Ser46 and Lys382 residues.
Ectopic expression of p300 rescues the p53 apoptotic gene 
transcription impaired by HIPK2 depletion
We hypothesized that HIPK2 might affect multiple p53
posttranslational modifications, in response to genotoxic
stress, to efficiently induce p53 apoptotic target gene tran-
scription. In particular, as acetylation of p53 C-terminal
lysines at position 373 and 382 by p300 stimulates these
activities [12,25,26], we tested whether ectopic p300 was
able to restore p53 apoptotic transcriptional activity in
siHIPK2 cells. We first analysed p53 conformation by
immunoprecipitation with conformation-specific anti-
body, as we showed that in the absence of HIPK2 p53
increases its mutant-like conformation that affects its
DNA-binding and transcriptional activities [22]. As
shown in Figure 3c, overexpression of p300 in siHIPK2
cells reduced the levels of unfolded (mutant-like) p53
conformation as detected by PAb240 antibody. We there-
fore reasoned that, by modifying the conformation of p53
in response to genotoxic stress, p300 could specifically
induce ADR-mediated Ser46 phosphorylation (likely by
additional kinases other than HIPK2) in addition to pro-
moting Lys382 acetylation, even in HIPK2 knockdown
background, and efficiently saturate low-affinity proapop-
totic promoters. Indeed, overexpression of p300 in
siHIPK2 cells induced both Lys382 acetylation and Ser46
phosphorylation in response to drug, reactivating the
apoptotic response, as assessed by PARP cleavage (Figure
3d). In support of our hypothesis, we performed luci-
ferase assay, in the absence of HIPK2, upon co-transfec-
tion of p300 with two p53-induced reporters related to
growth arrest (p21-luc and GADD45-luc) and two report-
ers related to apoptotic function (Noxa-luc and p53AIP1-
luc). ADR treatment did not induce luciferase activities of
any reporter analysed while zinc supplementation to ADR
treatment selectively induced the p21-luc and GADD45-
luc reporters (Figure 3e), as expected. Notably, p300 over-
expression in siHIPK2 cells specifically induced apoptotic
gene reporters in response to drug (Figure 3e). Finally, in
vivo  transcription of p53-apoptotic target genes in
response to ADR, greatly impaired in siHIPK2 cells
(+Dox) compared to control cells, was not reactivated by
zinc (Figure 4a); conversely, p21 and BTG2 gene expres-
sion was induced by ADR and zinc combination, as
expected (Figure 4a). Of note, p300 overexpression reacti-
vated p53 apoptotic transcription in response to ADR
(Figure 4b), while it did not induce p21 and BTG2 gene
expression (Figure 4b). In agreement, p300 overexpres-
sion in siHIPK2 cells significantly reactivated the ADR-
induced apoptotic response, as assessed by TUNEL assay
(Figure 4c). These results suggest that forced p53 acetyla-
tion in HIPK2-depleted cells can modify wild-p53 confor-
mation such that overcomes the inability of endogenous
p53 to activate apoptotic response to drug. This is also in
agreement with the role of HIPK2 in inducing both Ser46
and ac-Lys382 posttranslational modifications for p53
apoptotic gene transcription (Figure 3b). In agreement
with our results, it has been proposed that various p53
acetylation mutants possess different intrinsic affinities
for their downstream promoters; thus covalent modifica-
tions of p53 may change target gene preference by impos-
ing conformational changes in p53 that encourage
selective recognition of different p53 responsive elements
[27]. Particularly, acetylation of residues around positionMolecular Cancer 2009, 8:85 http://www.molecular-cancer.com/content/8/1/85
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Ectopic expression of p300 in HIPK2 knockdown rescues the p53Lys382 apoptotic transcriptional activity Figure 3
Ectopic expression of p300 in HIPK2 knockdown rescues the p53Lys382 apoptotic transcriptional activity. (a) 
RKO cells stable-transfected with p53AIP1-luc reporter were transfected with pSuper-HIPK2 (siHIPK2) or control pSuper 
(siRNA) vectors for 24 h and then treated with ADR (2 μg/ml) and zinc (150 μM) for 16 h before luciferase activity was 
assayed. Results are representative of three independent experiments performed in duplicate ± S.D. * P < 0.01. (b) H1299 cells 
were co-transfected with p53AIP1-luc reporter and HIPK2-Flag together with wtp53, Q373, R382, or A46Q373 mutants. Luci-
ferase activity was assayed 36 h thereafter. (c) RKO cells stable depleted of HIPK2 function were transfected with p300-Flag 
expression vector and treated with ADR for 16 h. Equal amount of total cell extracts were immunoprecipitated with confor-
mation-specific PAb240 (for p53 mutant, unfolded conformation) antibody and immunoblotted (IB) with anti-p53 (FL393) anti-
body (upper panel). Endogenous p300 (arrow) and ectopic p300-Flag protein levels were detected by immunoblotting (IB) 
equal amount of total cell extracts with anti-p300 antibody (lower panel), endogenous p53 levels were also detected. Anti-
tubulin was used as protein loading control (lower panel). (d) RKO cells stable depleted of HIPK2 function were transfected 
with p300-Flag expression vector and treated with ADR and zinc for 16 h. Equal amount of total cell extracts were immunob-
lotted with anti-phospho-Ser46, anti-acetyl-Lys382, anti-p53, and anti-PARP (arrows indicate the uncleaved and cleaved forms) 
antibodies. (e) RKO cells stable depleted of HIPK2 function were co-transfected with the indicated reporters along with p300 
expression vectors for 24 h and then treated with ADR for 16 h before luciferase activity was assayed. Results, normalized to 
β-galactosidase activity, are representative of three independent experiments performed in duplicate ± S.D. * P < 0.01.Molecular Cancer 2009, 8:85 http://www.molecular-cancer.com/content/8/1/85
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K382 is necessary for binding to low-affinity proapoptotic
promoters, it affects the ability to interact with cellular
proteins, including p300, and influences other key post-
translational modifications, such as Ser46 [27]. How
HIPK2 knockdown can affect p300-dependent p53Lys382
acetylation has not been clearly elucidated yet, although
previous studies have shown HIPK2/p300 interaction and
that HIPK2-mediated phosphorylation of p300 stimulates
its acetyl-transferase (HAT) activity [16].
Inhibition of Sirt1 with nicotinamide correlates with 
restored p53 apoptotic transcriptional activity in HIPK2 
knockdown
We hypothesized that HIPK2 may affect p53 apoptotic
activity by acting on structural rearrangements of p53 not
only through Ser46 phosphorylation but also by exposing
p53 C-terminus to p300 and therefore promoting acetyla-
tion and transcriptional function of p53 toward apoptotic
genes. However, since Lys382 is also a substrate of Sirt1
deacetylase whose regulation has not yet been fully eluci-
dated in tumorigenesis, we attempted to evaluate whether
lack of ac-p53Lys382 in our HIPK2 knockdown system
but could depend on increased deacetylase activity. To
verify this hypothesis, HIPK2-depleted cells were treated
with deacetylase inhibitors followed by Western immuno-
blotting and luciferase assays. As shown in Figure 5a, both
Ser46 phosphorylation and Lys382 acetylation were effi-
ciently obtained after combination of zinc and ADR with
nicotinamide (Nic), a physiologic inhibitor of Sirt1
deacetylase while trichostain A (TSA), the inhibitor of his-
tone deacetylase complexes (HDAC) did not affect these
modifications, indicating that Sirt1 is the potential
deacetylase involved. Moreover, while p21 expression was
induced after ADR and zinc combination, Bax expression
was induced only after adding nicotinamide to ADR and
zinc combination (Figure 5a). Luciferase assay in RKO-
HIPK2 depleted cells showed that Nic strongly induced
p53AIP1-luc reporter activity in combination with zinc
and ADR (Figure 5b), whereas TSA did not. Similar results
were obtained with H1299-HIPK2-depleted cells where
p53 was co-transfected with two reporters related to
growth arrest (p21-luc and GADD45-luc) and two report-
ers related to apoptotic function (Noxa-luc and p53AIP1-
luc) and treated with combination of ADR and zinc in the
presence of Nic or TSA inhibitors. As shown in Figure 5c,
strong p53-dependent induction of p21-luc and
GADD45-luciferase activity was obtained only after com-
bination of ADR and zinc, while Nic or TSA did not have
any relevant effect; on the contrary, p53-dependent induc-
tion of p53AIP1-luc and Noxa-luc activity was strongly
induced by adding Nic to ADR and zinc combination
treatment, while TSA did not have effect. These data sug-
gest that Sirt1 is the enzyme responsible for p53 deacetyla-
tion in our model and that p53 acetylation is necessary for
p53 apoptotic transcriptional activity, indeed, Nic to ADR
and zinc combination treatment shifted the p53 affinity
versus the apoptotic reporters.
The in vivo gene transcription and apoptosis were ulti-
mately measured by RT-PCR analysis and TUNEL assay.
As shown in Figure 6a, ADR in combination with zinc
induced p21 and BTG2 expression, while only addition of
nicotinamide to zinc supplementation strongly induced
Puma and Noxa mRNA expression in response to ADR, in
HIPK2-depleted cells, while TSA did not have relevant
effect. In agreement, addition of nicotinamide to ADR and
zinc combination significantly increased apoptotic
response of HIPK2 depleted cells, as assessd by Tunel
assay, while TSA did not have relevant effect (Figure 6b).
Taken together, these results indicate that the Sirt1-inhib-
itor nicotinamide can restore p53Lys382 acetylation in
HIPK2 depleted cells, and induce p53 apoptotic gene tran-
scription in response to ADR and zinc treatment improv-
ing the apoptotic response. These results suggest that
HIPK2 or HIPK2-regulated pathways may affect Sirt1
activity and therefore that HIPK2 might regulate the
acetylation/deacetylation balance of p53 through likely
independent pathways.
Discussion
In this paper we studied the interconnection between two
posttranslational modifications involved in p53 activa-
tion, that is Ser46 phosphorylation and Lys382 acetyla-
tion. We show that HIPK2 was needed for co-recruitment
of ac-p53 and p300 onto apoptotic gene promoters, in
response to drug, and that p53 acetylation at Lys382 was
required for successful interaction of p53 with its target
apoptotic promoters and for improving apoptotic
response. Furthermore, for the first time we show here
that HIPK2 may also regulate Sirt1 activity.
The best understood functions of p53 have been attrib-
uted to its transcriptional activity that undergoes different
levels of regulation mainly through posttranslational
modifications and protein-protein-interactions, in
response to DNA damage [28]. Previous data have indi-
cated that, upon severe DNA damage, phosphorylation of
Ser46 specifically favours transactivation of proapoptotic
genes [3] and we reported that HIPK2 is one of the kinases
that phosphorylate p53 at Ser46, thereby contributing to
the increased likelihood of cell death under severe DNA
damage [5]. Indeed, HIPK2 depletion by siRNA strongly
impairs p53 function, affecting not only Ser46 phosphor-
ylation [6] but also p53 wild-type conformation due to
deregulation of metallothionein and zinc [22,23]. In this
report, we have further investigated the p53 regulation
exerted by HIPK2 and highlighted a complex interplay
between HIPK2, p300, Sirt1 and p53 connecting HIPK2-
dependent Ser46 phosphorylation with Lys382 acetyla-
tion/deacetylation at which HIPK2 might fine-tune theMolecular Cancer 2009, 8:85 http://www.molecular-cancer.com/content/8/1/85
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apoptotic transcriptional activity of p53 in tumor cells
subjected to genotoxic stress. One important finding that
supports the interplay among HIPK2, p300 and p53
comes from a leukemogenesis model where the oncogene
CBFβ-SMMHC attenuates the p53 apoptotic function
after DNA damage and prevents p300 phosphorylation by
sequestering HIPK2 in the cytoplasm [29,30] which
becomes the mechanistic explanation of the attenuation
of the HIPK2/p53 apoptotic pathway in response to DNA
damage. Intriguingly, our finding that also Sirt1 deacety-
lase may be induced in HIPK2 knockdown highlighted
the existence of additional pathways regulated directly or
indirectly by HIPK2 that need to be further elucidated.
Sirt1 levels are increased in a number of tumor types
although only few mechanisms of Sirt1 regulation have
been described [31] highlighting the requirement for fur-
ther deciphering the genetic alterations that have occurred
during tumorigenesis that may affect Sirt1. Furthermore,
targeting of Sirt1 in tumors overexpressing the protein
might be advantageous specially when used in combina-
tion with other compounds that target the p53 pathway
and this is currently an intense area of investigation.
Covalent modifications of p53 may change target gene
preference by imposing conformational changes in p53
that encourage selective recognition of different p53
responsive elements [27]. Thus, various p53 acetylation
mutants possess different intrinsic affinities for their
downstream promoters. Particularly, acetylation of resi-
dues around position K373 is necessary for binding to
low-affinity proapoptotic promoters, it affects the ability
to interact with cellular proteins, including p300, and
influences other key posttranslational modifications, such
as Ser46 and Ser392 [27]. Notably, we show that HIPK2
influences p53 apoptotic gene transcription depending on
p53 site-specific acetylation as we observed more efficient
Noxa- and p53AIP1-luc activity of wtp53 and Q373
mutant, co-expressed with HIPK2 compared to the K382R
mutant that failed to induce luciferase activity (Figure 3b).
These results imply that both posttranslational modifica-
tions of p53, Ser46 phosphorylation and Lys382 acetyla-
tion, are required for full activation of apoptotic
transcription, as suggested by the analysed p53 apoptotic
target genes.
The most common mechanism for loss of p53 function is
through mutation, however, about half of all cancers
retain the ability to express normal p53 protein deregu-
lated by other mechanisms [32]. In this regard, HIPK2 is
often inactivated in tumors by multiple mechanism such
as gene downregulation [33,34], gene mutation [35], pro-
tein mislocalization [36] as well as by protein degradation
through MDM2 [37] or hypoxia-induced factors [38],
impairing the cellular response to drug and supporting
tumor progression. In addition, the malignant phenotype
Ectopic expression of p300 in HIPK2 knockdown rescues the  p53 apoptotic gene transcription Figure 4
Ectopic expression of p300 in HIPK2 knockdown res-
cues the p53 apoptotic gene transcription. (a) 
MCF7indsi/HIPK2 cells, untreated or treated with Dox for 
HIPK2 depletion and reconstitution (see Figure 2) were 
treated with ADR (2 μg/ml) and zinc (150 μM) for 16 h. 
Gene expression of p53 targets was analysed by semiquanti-
tative RT-PCR. GAPDH was used as a control for efficiency 
of RNA extraction and transcription. (b) RKO cells stable 
depleted of HIPK2 function were transfected with p300 and 
treated with ADR and zinc for 16 h. Gene expression of p53 
targets was analysed by semiquantitative RT-PCR. GAPDH 
was used as control. (c) RKO cell depleted of HIPK2 func-
tion by siRNA were transfected with p300 or with empty 
vector by using LipofectaminePlus. After transfection cells 
were trypsinized and replated and 24 h after transfection 
treated with ADR. Apoptosis was measured by TUNEL assay 
24 h after ADR treatment and shown as percentage of 
TUNEL positive cells. The results shown are representative 
of two independent experiments performed in duplicate, ± 
S.D.Molecular Cancer 2009, 8:85 http://www.molecular-cancer.com/content/8/1/85
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Nicotinamide reconstitutes p53Lys382 acetylation and apoptotic transcriptional activity Figure 5
Nicotinamide reconstitutes p53Lys382 acetylation and apoptotic transcriptional activity. (a) RKO cells stable 
depleted of HIPK2 function were treated with ADR (2 μg/ml) and zinc (150 μM) for 16 h in the presence of nicotinamide (Nic) 
or TSA. Equal amounts of nuclear extracts were analysed by Western immunoblotting of Lys382, Ser46, total p53, p21 and 
Bax. Hsp70 represents protein loading control. (b) RKO cells stable depleted of HIPK2 function were transfected with 
p53AIP1-luc reporter for 24 h and treated with ADR and zinc for 16 h in the presence of Nic or TSA before luciferase activity 
was assayed. Results, normalized to β-galactosidase activity, are representative of three independent experiments performed in 
duplicate ± S.D. * P < 0.01. (c) H1299 cells stable depleted of HIPK2 function were co-transfected with low amount of wtp53 
expression vector and p21-luc, GADD45-luc, p53AIP1-luc, and Noxa-luc reporters and 24 h after transfection treated with 
ADR and zinc for 16 h in the presence of Nic or TSA before luciferase activity was assayed. Results, normalized to β-galactos-
idase activity, are representative of three independent experiments performed in duplicate ± S.D. * P < 0.01.Molecular Cancer 2009, 8:85 http://www.molecular-cancer.com/content/8/1/85
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was shown in HIPK2 heterozygous mice [39], suggesting
that HIPK2 may restrain tumor development and progres-
sion by acting on multiple different but sometime inter-
connected pathways. However, we recently reported that
hypoxic-induced HIPK2 inhibition can be completely
restored by zinc supplementation that reactivates p53
apoptotic response to drug [40], hypothesizing that
HIPK2 gene or protein inactivation can make a big differ-
ence in rescuing p53 activity and therefore tumor
response to drug in terms of therapeutical strategies.
Therefore, our studies not only provide a view of the mul-
tiple levels at which HIPK2 might fine-tune the transcrip-
tional activity of p53 in tumor cells subjected to genotoxic
stress, including the novel acetylation/deacetylation bal-
ance and Sirt1 regulation, but also may be relevant for
designing new strategies for treatment of tumors with
non-functional wtp53 and/or HIPK2.
Conclusion
As the knowledge of p53 activation by posttranslational
modification and protein/protein interactions grows the
challenge is to translate all this information into efficient
anticancer therapies. Our data suggest that a decrease of
HIPK2 levels is indicative of negative response to drug
therapy of cancer cells with wtp53 as it deeply affects p53
posttranslational modifications and therefore p53 tran-
scriptional activity. Many studies have recently focused on
pharmacological strategies aimed at restoring p53 tran-
scriptional function to look for new therapeutic
approaches to be translating in the clinic [41]. Therefore,
our results may represent an improvement to cancer ther-
apy by combining pharmacological or natural agents with
standard therapies to be applied in the clinic for the
potential reactivation of wtp53 function in tumors.
Methods
Cell cultures and treatments
RKO, MCF7, and H1299 (p53/null) were cultured in
RPMI-1640 (GIBCO-Invitrogen) supplemented with 10%
fetal bovine serum (GIBCO-Invitrogen), glutamine and
antibiotics. Doxycycline (Dox)-inducible MCF7
(MCF7indsi/HIPK2) cell line expressing HIPK2-interfer-
ence has been described [23]. For inducible HIPK2 knock-
down Dox (1 μg/mL) was added to MCF7indsi/HIPK2
cells every 3 days until HIPK2 knockdown was success-
fully reached (usually in about 5 days). After HIPK2
knockdown was reached, cells were cultured without Dox
for additional 5 days before harvesting and processing for
RT-PCR and ChIP analyses. Stable HIPK2 interference was
obtained in RKO and H1299 cells after transfection of
pSuper-control and pSuper-HIPK2 vectors and selected as
mix population, as reported [6]. RKO cells were stably
transfected with the p53AIP1-luc reporter along with
pBabe-puro vector (1:10 molar/ratio), as reported [42].
Twenty-four hours after transfection puromicin (2 μg/ml)
was added to the cell culture medium for selection. Dox (1
μg/mL), Adriamycin (ADR, 2 μg/ml), ZnCl2 (150 μM),
nicotinamide (Nic, 5 mM) and Trichostatin A (TSA, 100
nM) all from SIGMA (St. Louis, MO, USA), were used as
indicated.
Plasmids and mutagenesis
The following expression vectors and reporter plasmids
were used: pSuper and pSuper-HIPK2 [6], HIPK2-Flag [5]
p300-Flag (kindly provided by M. Fanciulli, Regina Elena
Cancer Institute, Rome, Italy), pcDNA3-wtp53, K382R
(lysines 381 and 382 mutated to arginine) and p53Q373
(lysines 370, 372, and 373 mutated to glutamine), and
A46Q373 (serine 46 mutated to alanine in Q373 vector)
were generated by using PCR-based site-directed muta-
genesis (Qiagen, Crawley, UK), p53AIP1-luc (kindly pro-
vided by H. Arakawa, National Cancer Center, Tokyo,
Japan), Noxa-luc (kindly provided by T. Shibue, Graduate
School of Medicine, University of Tokyo, Japan), p21-luc
(kindly provided by B. Vogelstein, Johns Hopkins Univer-
sity, Baltimore, MD, USA), and GADD45-luc (kindly pro-
vided by K. Sabapathy, National Cancer Centre,
Singapore).
Transfection and transactivation assay
Transient or stable transfection were carried using the cal-
cium phosphate methods or the cationic polymer Lipo-
fectaminePlus reagent (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer's instructions. The amount
of plasmid DNA in each sample was equalized by supple-
menting with empty vector.
For transactivation assay cells were co-transfected with the
reported expression vectors along with the luciferase
reporter gene driven by p53-target promoters. Transfec-
tion efficiency was normalized with the use of a co-trans-
fected β-galactosidase (β-gal) plasmid. Luciferase activity
was assayed on whole cell extract and the luciferase values
were normalized to β-galactosidase activity and protein
content. At least three independent experiments were per-
formed in duplicate.
Chromatin Immunoprecipitation (ChIP) and Re-ChIP 
Assays
ChIP and Re-ChIP assays were performed as described
[43]. Protein complexes were cross-linked to DNA in liv-
ing cells by adding formaldehyde directly to the cell cul-
ture medium at 1% final concentration. Chromatin
extracts containing DNA fragments with an average size of
500 bp were incubated overnight at 4°C with milk shak-
ing using polyclonal anti-p53 (FL393, Santa Cruz Biotech-
nology), antiserum anti-acetyl-p53 (Lys373&382)
(Upstate), polyclonal anti-acetyl-p53 (Lys382) (Cell Sign-
aling), monoclonal anti-p300 CT (clone RW128)
(Upstate), and antiserum anti-PAN-acetylated Histone 4Molecular Cancer 2009, 8:85 http://www.molecular-cancer.com/content/8/1/85
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(ac-H4, Upstate) antibodies. DNA-protein complexes
were recovered with protein G Agarose (Pierce). PCR was
performed with HOT-MASTER Taq (Eppendorf) using 2
μL of immuniprecipitated DNA and promoter-specific
primers for for the p53 target promoters. In each experi-
ment, the linearity of the signal was insured by amplifica-
tion of increasing amounts of template DNA.
Immunoprecipitation with non-specific immunoglobu-
lins (IgG; Santa Cruz Biotechnology) was performed as
negative controls. The amount of precipitated chromatin
measured in each PCR was normalized with the amount
of chromatin present in the input of each immunoprecip-
itation. PCR products were run on a 2% agarose gel and
visualized by ethidium bromide staining using UV light.
RNA Extraction and Reverse-Transcription (RT) PCR
Total RNA was extracted with TRIzol (Invitrogen) follow-
ing the manufacturer's instructions. The first strand cDNA
was synthesized by reverse-transcribing 5 μg of mRNA
with Moloney murine leukaemia virus reverse tran-
scriptase kit and random primers (Applied Biosystems).
Semiquantitative RT-PCR was carried out by using Hot-
Master Taq (Eppendorf) with 2 μl cDNA reaction and
genes specific oligonucleotides under conditions of linear
amplification. DNA products were run on 2% agarose gel
and visualized by ethidium bromide staining using UV
light. Data presented are representative of at least three
independent experiments.
TUNEL assay
For TUNEL assay, 4 × 104 cells were spun on a slide by
cytocentrifugation and subsequently fixed in 4% parafor-
maldehyde for 30 min at room temperature. After rinsing
with PBS the samples were permeabilized in a solution of
0.1% Triton X-100 in sodium citrate for 2 min. Samples,
washed with PBS, were then incubated in the TUNEL reac-
tion mix for 1 h at 37°C, according to the manufacturer's
instructions (Roche, Germany). Cells were counter-
stained with Hoechst 33342 before analysis with a fluo-
rescent microscope (Zeiss). Standard deviations of three
independent experiments were indicated.
Western Blotting and p53 conformational 
immunoprecipitation
Total cell extracts and subcellular fractionations were car-
ried out as [34]. Proteins were then separated by 4-10%
gradient SDS-PAGE (BioRad) and blotted onto nitrocellu-
lose membrabe (BioRad). The membranes were probed
with a primary antibody followed by horseradish-peroxi-
dase conjugated secondary antibody. Immunoreactivity
was detected with the ECL-chemoluminescence reaction
kit (Amersham). The antibodies used were: monoclonal
anti-p53 (DO1), polyclonal anti-p53 (FL393), polyclonal
anti-Bax, polyclonal anti-p21 (Santa Cruz Biotechnol-
(a) RKO cells stable depleted of HIPK2 function (siHIPK2)  were treated with ADR and zinc for 16 h in the presence of  Nic or TSA Figure 6
(a) RKO cells stable depleted of HIPK2 function 
(siHIPK2) were treated with ADR and zinc for 16 h in 
the presence of Nic or TSA. Gene expression of p53 tar-
gets was analysed by semiquantitative RT-PCR. GAPDH was 
used as a control for RNA extraction and transcription. (b) 
RKO cells HIPK2-depleted were treated as in (a) and apop-
tosis was measured by TUNEL assay 24 h after treatments 
and shown as percentage of TUNEL positive cells. The 
results shown are representative of two independent experi-
ments performed in duplicate, ± S.D.Molecular Cancer 2009, 8:85 http://www.molecular-cancer.com/content/8/1/85
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ogy), polyclonal anti-p53Ser46 (Cell Signaling), polyclo-
nal anti-acetyl-p53 (Lys382) (Cell Signaling),
monoclonal anti-p300 CT (clone RW128) (Upstate),
monoclonal anti-poly(ADP-ribose) polymerase (PARP,
BD PharMingen), monoclonal anti-tubulin (Immunolog-
ical Sciences), and monoclonal anti Hsp70 (Stressgene).
Conformational immunoprecipitation was essentially
performed as [22]. Briefly, 150-250 mg of total cell
extracts were immunoprecipitated with conformation-
specific monoclonal antibody PAb240 (mutant specific)
(Calbiochem). Immunocomplexes were separated by
10% SDS-PAGE and immunoblotting was performed
with rabbit anti-p53 antibody (FL393) (Santa Cruz).
Immunoreactivity was detected with the ECL-chemolumi-
nescence reaction kit (Amersham).
Statistics
All experiment unless indicated were performed at least
three times. All experimental results were expressed as the
arithmetic mean and standard deviation (s.d.) of meas-
urements was shown. Student's t-test was used for statisti-
cal significance of the differences between treatment
groups. Statistical analysis was performed using analysis
of variance at 5% (p < 0.05) or 1% (p < 0.01).
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